EE05537B1 - Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseks - Google Patents
Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseksInfo
- Publication number
- EE05537B1 EE05537B1 EEP200300355A EEP200300355A EE05537B1 EE 05537 B1 EE05537 B1 EE 05537B1 EE P200300355 A EEP200300355 A EE P200300355A EE P200300355 A EEP200300355 A EE P200300355A EE 05537 B1 EE05537 B1 EE 05537B1
- Authority
- EE
- Estonia
- Prior art keywords
- neublastin
- methods
- polymeric conjugates
- conjugates
- polymeric
- Prior art date
Links
- 102100026376 Artemin Human genes 0.000 title 1
- 101000785776 Homo sapiens Artemin Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Psychology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26607101P | 2001-02-01 | 2001-02-01 | |
| PCT/US2002/002319 WO2002060929A2 (en) | 2001-02-01 | 2002-01-25 | Polymer conjugates of neublastin and methods of using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EE200300355A EE200300355A (et) | 2003-10-15 |
| EE05537B1 true EE05537B1 (et) | 2012-04-16 |
Family
ID=23013042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200300355A EE05537B1 (et) | 2001-02-01 | 2002-01-25 | Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseks |
Country Status (35)
| Country | Link |
|---|---|
| EP (2) | EP1862475A1 (bg) |
| JP (2) | JP4259868B2 (bg) |
| KR (2) | KR100872807B1 (bg) |
| CN (1) | CN1500095B (bg) |
| AR (1) | AR035077A1 (bg) |
| AT (1) | ATE365748T1 (bg) |
| AU (1) | AU2002247037B2 (bg) |
| BG (1) | BG66393B1 (bg) |
| BR (1) | BR0206852A (bg) |
| CA (1) | CA2436407C (bg) |
| CY (1) | CY1106886T1 (bg) |
| CZ (1) | CZ20032080A3 (bg) |
| DE (1) | DE60220879T2 (bg) |
| DK (1) | DK1355936T3 (bg) |
| EA (1) | EA009771B1 (bg) |
| EE (1) | EE05537B1 (bg) |
| ES (1) | ES2289091T3 (bg) |
| GE (1) | GEP20063916B (bg) |
| HU (1) | HU228973B1 (bg) |
| IL (2) | IL156941A0 (bg) |
| IS (1) | IS2867B (bg) |
| MX (1) | MXPA03006805A (bg) |
| MY (1) | MY143685A (bg) |
| NO (1) | NO332150B1 (bg) |
| NZ (1) | NZ527863A (bg) |
| PL (1) | PL211162B1 (bg) |
| PT (1) | PT1355936E (bg) |
| RS (1) | RS50857B (bg) |
| SG (1) | SG149685A1 (bg) |
| SI (1) | SI1355936T1 (bg) |
| SK (1) | SK288123B6 (bg) |
| TR (1) | TR200301208T2 (bg) |
| UA (2) | UA82983C2 (bg) |
| WO (1) | WO2002060929A2 (bg) |
| ZA (1) | ZA200305733B (bg) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
| TR200301208T2 (tr) * | 2001-02-01 | 2005-05-23 | Biogen, Inc. | Nublastin polimer eşlenikleri ve bunları kullanma yöntemleri. |
| US7276580B2 (en) | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
| ES2374971T3 (es) * | 2001-03-28 | 2012-02-23 | Biogen Idec Ma Inc. | Uso de polipéptidos de neublastina para el tratamiento del dolor neuropático. |
| DK3025726T3 (da) * | 2002-01-18 | 2019-12-09 | Biogen Ma Inc | Polyalkylenpolymerforbindelser og anvendelser deraf |
| DE602004028801D1 (de) * | 2003-01-31 | 2010-10-07 | Biogen Idec Inc | Neublastin-mutanten |
| WO2004094592A2 (en) | 2003-04-18 | 2004-11-04 | Biogen Idec Ma Inc. | Polymer-conjugated glycosylated neublastin |
| ATE423134T1 (de) | 2003-06-10 | 2009-03-15 | Nsgene As | Verbesserte sezernierung von neublastin |
| US7598059B2 (en) | 2003-10-02 | 2009-10-06 | Biogen Idec Ma Inc. | Neublastin expression constructs |
| KR101215697B1 (ko) * | 2004-08-19 | 2012-12-28 | 바이오겐 아이덱 엠에이 인코포레이티드 | 뉴블라스틴 변형체 |
| KR101241551B1 (ko) * | 2004-08-19 | 2013-03-11 | 바이오겐 아이덱 엠에이 인코포레이티드 | 전환 성장 인자 베타 패밀리 단백질의 리폴딩 |
| TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
| ES2450065T3 (es) * | 2006-03-01 | 2014-03-21 | Biogen Idec Ma Inc. | Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF |
| HRP20110487T1 (hr) | 2006-09-15 | 2011-08-31 | Creabilis Therapeutics S.R.L. | Polimerni konjugati hmgb1 box-a i varijanti hmgb1 box-a |
| ES2476253T3 (es) | 2007-05-01 | 2014-07-14 | Biogen Idec Ma Inc. | P�ptidos de neublastina para su uso en el aumento de la vascularizaci�n en tejido con flujo sanguíneo deteriorado |
| EP3527274B1 (en) * | 2011-11-02 | 2025-12-24 | F. Hoffmann-La Roche AG | Overload and elute chromatography |
| RU2488635C1 (ru) * | 2012-03-22 | 2013-07-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития | Способ получения рекомбинантного антиангиогенного полипептида |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6472178B1 (en) * | 1998-02-27 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof |
| US5770577A (en) * | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
| US6593133B1 (en) * | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
| WO2000034475A2 (en) * | 1998-12-09 | 2000-06-15 | Amgen Inc. | Grnf4, a gdnf-related neurotrophic factor |
| TR200301208T2 (tr) * | 2001-02-01 | 2005-05-23 | Biogen, Inc. | Nublastin polimer eşlenikleri ve bunları kullanma yöntemleri. |
-
2002
- 2002-01-25 TR TR2003/01208T patent/TR200301208T2/xx unknown
- 2002-01-25 MX MXPA03006805A patent/MXPA03006805A/es active IP Right Grant
- 2002-01-25 DK DK02714792T patent/DK1355936T3/da active
- 2002-01-25 AT AT02714792T patent/ATE365748T1/de active
- 2002-01-25 SG SG200504719-6A patent/SG149685A1/en unknown
- 2002-01-25 KR KR1020037010127A patent/KR100872807B1/ko not_active Expired - Fee Related
- 2002-01-25 CN CN028077539A patent/CN1500095B/zh not_active Expired - Fee Related
- 2002-01-25 AR ARP020100279A patent/AR035077A1/es not_active Application Discontinuation
- 2002-01-25 KR KR1020087022638A patent/KR100960063B1/ko not_active Expired - Fee Related
- 2002-01-25 PL PL372101A patent/PL211162B1/pl unknown
- 2002-01-25 SK SK971-2003A patent/SK288123B6/sk not_active IP Right Cessation
- 2002-01-25 PT PT02714792T patent/PT1355936E/pt unknown
- 2002-01-25 HU HU0500637A patent/HU228973B1/hu not_active IP Right Cessation
- 2002-01-25 ES ES02714792T patent/ES2289091T3/es not_active Expired - Lifetime
- 2002-01-25 WO PCT/US2002/002319 patent/WO2002060929A2/en not_active Ceased
- 2002-01-25 AU AU2002247037A patent/AU2002247037B2/en not_active Ceased
- 2002-01-25 GE GE5240A patent/GEP20063916B/en unknown
- 2002-01-25 BR BR0206852-4A patent/BR0206852A/pt not_active Application Discontinuation
- 2002-01-25 UA UA2003088104A patent/UA82983C2/ru unknown
- 2002-01-25 EP EP07110666A patent/EP1862475A1/en not_active Withdrawn
- 2002-01-25 IL IL15694102A patent/IL156941A0/xx unknown
- 2002-01-25 SI SI200230580T patent/SI1355936T1/sl unknown
- 2002-01-25 NZ NZ527863A patent/NZ527863A/en not_active IP Right Cessation
- 2002-01-25 EA EA200300852A patent/EA009771B1/ru not_active IP Right Cessation
- 2002-01-25 EP EP02714792A patent/EP1355936B1/en not_active Expired - Lifetime
- 2002-01-25 EE EEP200300355A patent/EE05537B1/xx not_active IP Right Cessation
- 2002-01-25 RS YUP-610/03A patent/RS50857B/sr unknown
- 2002-01-25 CA CA2436407A patent/CA2436407C/en not_active Expired - Fee Related
- 2002-01-25 UA UAA200802148A patent/UA100967C2/ru unknown
- 2002-01-25 DE DE60220879T patent/DE60220879T2/de not_active Expired - Lifetime
- 2002-01-25 JP JP2002561497A patent/JP4259868B2/ja not_active Expired - Fee Related
- 2002-01-25 CZ CZ20032080A patent/CZ20032080A3/cs unknown
- 2002-02-04 MY MYPI20020368A patent/MY143685A/en unknown
-
2003
- 2003-07-15 IL IL156941A patent/IL156941A/en not_active IP Right Cessation
- 2003-07-17 IS IS6879A patent/IS2867B/is unknown
- 2003-07-24 ZA ZA2003/05733A patent/ZA200305733B/en unknown
- 2003-08-01 NO NO20033441A patent/NO332150B1/no not_active IP Right Cessation
- 2003-08-19 BG BG108111A patent/BG66393B1/bg unknown
-
2007
- 2007-09-21 CY CY20071101225T patent/CY1106886T1/el unknown
-
2008
- 2008-10-28 JP JP2008277469A patent/JP4423338B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200300145A (et) | Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon | |
| EP1298180A4 (en) | HYDROPHOBIC AND LIPOPHOBE COMPOSITION | |
| EE200300528A (et) | Cripto valku blokeerivad antikehad ja nende kasutamine | |
| EE200200251A (et) | Uued N-asabitsükloamiidi derivaadid ja nende kasutamine | |
| EP1412378A4 (en) | APTAMERS AND ANTIAPTAMERS | |
| DK1417175T3 (da) | Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf | |
| DE60208351D1 (de) | Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung | |
| DE60230591D1 (de) | Glykopyranosyloxypyrazolderivate und deren medizinische verwendung | |
| DE60237580D1 (de) | Glykopyranosyloxypyrazolderivate und deren medizinische verwendung | |
| CY2013032I1 (el) | Συζυγη της εξενδινης-4 και η φαρμακευτικη τους χρηση | |
| EE200200341A (et) | Asendatud oksasolidinoonid ja nende kasutamine | |
| EP1383518A4 (en) | ORAL DELIVERY OF MACROMOLECULES | |
| EE200200626A (et) | Antraniilamiidid ja nende kasutamine ravimitena | |
| EE200300311A (et) | Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim | |
| EE200300355A (et) | Neublastiini polümeerkonjugaadid ja meetodid nende kasutamiseks | |
| EE05333B1 (et) | Makroliidhendite konjugaadid p?letikuvastaste henditega ja nende kasutamine | |
| EE200300193A (et) | Asendatud bensimidasoolid, nende kasutamine ja ravim | |
| FI20011671A0 (fi) | Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö | |
| DE60208700D1 (de) | Schälgerät und zugehörige verfahren | |
| DE60217539D1 (de) | Leichtathletikschuh | |
| EE200300339A (et) | Helicobacter pylory uudsed retseptorid ja nende kasutamine | |
| ITMI20010045U1 (it) | Spazzolino da denti perfezionato | |
| NO20030156D0 (no) | Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav | |
| ATE299873T1 (de) | Substituierte c-furan-2-yl-methylamin- und c- thiophen-2-yl-methylamin-derivate | |
| FI20012016L (fi) | Eettereitä hajottavia bakteereita ja niiden käyttö |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC1A | Change of owner name | ||
| MM4A | Lapsed by not paying the annual fees |
Effective date: 20160125 |